(18) From Study to Standard of Care: A Blinatumomab Success Story

Title: From Study to Standard of Care: A Blinatumomab Success Story

Abstract : The Children’s Oncology Group (COG) AALL1731 trial demonstrated significant improvement in disease-free survival, establishing blinatumomab as a new standard of care for standard-risk B-cell acute lymphoblastic leukemia (B-cell ALL) patients. While this breakthrough represented a major advancement, the rapid translation of trial findings into clinical practice posed significant challenges. Systemic barriers, including payer variability, prior authorization delays, and logistical hurdles, complicated timely access to this life-saving therapy. This project showcases a collaborative success story while highlighting lessons for future improvements.
This quality improvement project aimed to identify and overcome systemic barriers to integrating blinatumomab into practice. This initiative reviewed institutional processes for patient advocacy, optimized outpatient and home infusion protocols, and engaged multidisciplinary collaboration to establish scalable strategies for future therapeutic integration.
A retrospective analysis was conducted on patients treated with Blinatumomab between 2019 and 2024, identifying successes in current processes and challenges in implementing this therapy. Key variables included demographic factors (e.g., race, ethnicity, socioeconomic indicators), insurance details (e.g., prior authorization timelines, rejections, appeals), and clinical metrics (e.g., ANC, platelets, and cycle delays), while also examining the role of social work interventions and systemic factors affecting treatment delays. Additionally, addressing the issue of infusion line breakage, a rapid PDSA cycle was implemented.
Twenty-two patients received Blinatumomab at this institution. Between July and October 2024, nine high-risk and three standard-risk patients transitioned to blinatumomab. A multidisciplinary collaboration among physicians, nurses, pharmacists, financial staff, and administrative leaders resulted in an average time of 34 days (maximum 50 days) from prior authorization request to approval, streamlining access to therapy. Coordinated efforts ensured provision of dedicated infusion pumps, comprehensive patient education, and optimization of infusion protocols. A rapid PDSA cycle resolved infusion line breakage by discontinuing Equashield. These outcomes clearly underscore the essential team-based approach in overcoming systemic barriers when integrating practice-changing therapies.